

Ovarian Cancer: Effective Practices to Benefit Patients

- In advanced ovarian cancer, genetic testing rates hover around 50%.¹
- Only 49% of patients received maintenance therapy in second line or greater therapy.²
- Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time.
 - **NCODA's Positive Quality Intervention (PQI)** on this topic provides practical guidance and is available here: www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility

This EMR Resource provides simple step-by-step instructions to:

 **1. Run a Report:** to search for all ovarian cancer patients

 **2. Review Chart:** to conduct a clinical assessment

 **3. Create Reminders and Track:** key treatment milestones and timing of therapy

1. Run a Report

To identify all ovarian cancer patients within the EMR, search by "Ovarian"

From the open patient menu on the horizontal tab bar, select **Patient** → select **Advanced**

From Criteria Categories select **Problem Presence**

Under Problems select **Ovarian** → to the right select **Present**

On the right, select **Add** → select **OK**


From open patient menu, **Ovarian is = Present** is now in the search box

Select **Patient** → select **Search**

Results will populate a list of ovarian cancer patients (active, progressed, or controlled)


2. Review Chart

From the patient list, select a patient and review each patient case to determine



3. Create Reminders and Track

For each patient, create a tracking system and reminder flag via “Reminders” function



1. Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer before and after PARP inhibitor approvals. Presented at the 17th Biennial Meeting of the International Gynecologic Cancer Society; Kyoto, Japan: 2018.
 2. Garofalo D, Verma-Kurvari S, Aydin E, et al. Real world data analysis of ovarian cancer maintenance utilization among maintenance eligible patients. Presented at the American Society of Clinical Oncology Annual Congress; Chicago, IL: 2019.

